ClinicalTrials.gg
CompletedNCT05052476BACTECOLICUpdated Nov 28, 2023

First Line Dose-efficacy Study of Bactecal® D Liquid for Infant Colic

An interventional study of Bactecal® D Liquid in Colic, sponsored by Astel Medica. Completed at 1 site in Belgium. Open to participants aged 2 Weeks to 8 Weeks. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by Astel Medica · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
2 Weeks to 8 Weeks
Sex
All
01

Study summary

This randomized, open label, dose-response study will be realized at the first line with Bactecal® D Liquid. The objective is to investigate Bactecal® D Liquid in the context of infantile colics.

The patients will be randomized into two arms, A and B, in function of the intervention dose. The quality of life of te parents as well as the daily median crying time and the number of daily crying will be assessed.

02

Conditions studied

  • Colic

Browse trials for

03

In context

Colic

127 studies on the registry are indexed under Colic; 18 are open to participants now.

This study's enrollment of 68 is below the median of 76 across 110 interventional studies indexed under Colic.

Browse Colic studies →

Lead sponsor

This is the only study on the registry with Astel Medica as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Weeks to 8 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Full term healthy infant (37-41 weeks amenorrhea)
  • Birth weight >2750 g
  • Aged between 2 and 8 weeks
  • Presenting symptoms of infant colic as defined by Rome IV criteria by Zeevenhoven et al. 2017
  • Signed written of the parent/tutor

Exclusion criteria

Exclusion Criteria:

  • Premature birth
  • Using probiotics as a treatment, different from the one that could contain the formula at the time of study recruitment
  • Acute or chronic illness as judged by the investigator which avoids the participation to the study .
  • Parents unable to understand the requirements of study participation as judged by the investigator
  • Malnutrition as judged by a body weight/height ratio \<5 %
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Open label Bactecal® D Liquid 1 dose

    Patients will receive 1 dose of Bactecal® D Liquid by day which corresponds to 2 ml of product

    Dietary Supplement: Bactecal® D Liquid

  • Experimental
    Open label Bactecal® D Liquid 2 doses

    Patients will receive 2 doses of Bactecal® D Liquid by day which correspond to 4 ml of product.

    Dietary Supplement: Bactecal® D Liquid

Interventions

  • Dietary supplementBactecal® D Liquid

    The patients will be randomized into two arms, A and B, in function of the intervention dose

06

What researchers measure

Primary outcomes

  1. Change in parent quality of life (QoL) score

    By measuring parent quality of Life (QoL) score. Scale from 1 (minimum) to 7 (maximum). Higher scores mean a better outcome.

    Time frame: Change from baseline parent QoL score at 28 days

Secondary outcomes

  1. Change of daily median crying time

    By measuring the mean change in crying time

    Time frame: Change from baseline daily median crying time at 28 days

  2. Change of the number of crying

    By measuring the numbers per day

    Time frame: Change from baseline number of crying at 28 days

07

Study locations

1 site
  • UZ Brussel
    Brussel, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05052476
Lead sponsor
Astel Medica
Responsible party
Sponsor
First posted
Sep 22, 2021
Start date
Apr 8, 2022
Primary completion
Oct 8, 2023
Completion
Oct 16, 2023
Last update
Nov 28, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion